News

Antabio Highlights New Data on their Novel β‑lactam/β‑lactamase Inhibitor, Meropenem-Pilabactam (formerly Meropenem-ANT3310) at the 36th Congress of the European Society of Clinical Microbiology and Infectious Diseases 

Antabio and GARDP join forces to identify potential next-generation antibiotics 

Antabio Announces Successful Completion of Phase 1 Clinical Study of MEM-ANT3310 for Severe Hospital Infections

The positive Phase 1 data -including good tolerability and matching PK between ANT3310 and meropenem- supports further patient studies of...

ANTABIO Announces Appointment of Dr. Erick Lelouche as Chairman of the Board

ANTABIO Raises €25 million in Series B Financing

Led by the AMR Action Fund, with subscriptions from the EIC Fund and from Antabio’s historical investors, the financing will...

Antabio Announces First Subjects Dosed in Phase 1 Clinical Trial of MEM-ANT3310, a Highly Differentiated Antibiotic for Severe Hospital Infections

Launch of ARPEGE, a French multidisciplinary consortium to fight antibiotic resistance through preventive, diagnostic, therapeutic and economic approaches

Led by Antabio, acting jointly with bioMérieux, Hospices Civils de Lyon, and Toulouse School of Economics, the four-year ARPEGE project...

Antabio Awarded EUR 0.9 million funding from the Occitanie Region to support the Preclinical Development of MEM-ANT3310, Antabio’s Novel Broad-Spectrum Combination Therapy Targeting WHO’s Priority Pathogens

ANT3310 is a novel, potent and specific inhibitor of bacterial Serine Beta-Lactamases (SBLs) which displays excellent inhibitory activity against both...

Antabio Receives FDA Qualified Infectious Disease Product (QIDP) Designation for MEM-ANT3310, a Novel Broad-Spectrum Combination Therapy Targeting WHO’s Priority Pathogens